Can a PET scan predict lung cancer treatment success after just one dose?
NCT ID NCT03832348
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This study looked at 40 adults with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Researchers used PET scans after the first dose of the immunotherapy drug pembrolizumab to see if early changes in tumor sugar uptake could predict whether the cancer would respond to treatment after three months. The goal was to find a faster way to tell if the drug is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU
Rouen, 76000, France
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.